昭衍新药2025中期报告

2 5 6 8 9 10 29 40 42 44 46 47 H1.00 20212 16 20256 30 H 1617 20251 2320251 23 20251 2320251 2320251 2320251 2320251 2320251 23 5100176 33191920 5100176 H6127A603127 15323203-3207 108 35A509100033 https://www.joinnlabs.com 2025 668.660.9202510.213.3%5.918.0%20%ADC50%(CNS)23 20258 26 I. 20252310.22025 1.2.20%3.ADC50%4.(CNS)5.6.7. 2025 1. (1) NMPAFDAOECDMFDSPMDAGLPGLP 20257CMAFDAOECD GLPFDA (2) AMD PDE3/4 GLP-1GCGHPVPBMC GLP-1R/GCGR/GIPRGLP-1RGCGR GIPR MSDADCPEGGC-MS/MSELISAqPCRELISPOT WB FLOWmRNAsiRNAPCRmRNA ADCPROTAC (3) BADC 300-500mgProtein A BPCR10X genomics B (ADC)INDADCADCADC 20 FDAEMA 2025 2. CROCRO ADCPROTAC 2025IIITCEPKPK 2025120254CNAS 1702511 3. (1) 2025(allo-HSCT)(GvHD) (2) (Nano-antibody) (3) 3R2025(CiPSCs) AI 4. 12CNASGLP CHO/3T3NK2022IIT/CBPIA 0008–2024T/CBPIA 0011–2025 CDEFDA 1 202520256 302,551 2 400 II20,00020,000 II. 20256 30668.620246 30849.421.3% 20256 30563.620246 30638.111.7% 20256 30105.015.7%20246 30211.324.9%20256 30 20256 3082.920246 3080.13.5%20256 30 20256 3095.020246 30254.4202563020246 30 20256 3014.620246 3012.220.1% 20256 30143.92024630168.614.6%20256 30 20256 3043.420246 3047.89.2%20256 30 20256 300.820246 301.237.9% 20256 3019.220246 305.1 20256 3023.9%20246 302.9%2024630 20246 30172.220256 3060.920246 30-20.3%20256 309.1% 20256 30662.2202412 31965.231.4% 20256 3014.4%202412 3114.0% 20256 302,551 294.62024284.3 20256 3020256 3093.42024106.1 20256 30 20256 30 20256 30 III. IV. CROCRO 1. (1)2025GLP (2) (3)PCC;FDA/EMAADMEPK-PDLC-MS/MSPDPKAI (4)GLP (5)2025 2. GLPGCP (1) (2)(3)(4) 3. (1) (2)2025 (3) 20256 30 13.1313.14 13.15 13.20 13.21 20256 30XV352 (1)A167,160,633A20256 3022.30%74,725,981A20256 309.97%3,303,034A20256 300.44%245,189,64820256 3032.71%(2)L(3)2025630749,477,334630,482,128A3,303,034118,995,206H 20256 30XVXV78352 20256 30XV233365% (1)LP(2)2025630749,477,334630,482,128A3,303,034118,995,206H(3)(1)(4)Pandanus Associates Inc.Pandanus Partners L.P. 100%Pandanus Partners L.P.FIL Limited 47.90%FIL LimitedFIL Investment Management (Hong Kong) Limited 93.62%FIDELITY FUNDSFIL Investment Management (Hong Kong)LimitedFIDELITY FUNDS15,495,100HFIL Limited1,502,700HPandanus Associates Inc.Pandanus Partners L.P.FIL LimitedFIL Limited 20256 30XV233365% 2022H 20226 242022H (a) 2022H(i)(ii)(iii) (b) 2022HH (c) (d) 2022HH (e) 2022H600H H 2022H (f) 2022H (i)(ii)(iii) (g) 2022H2022H20226 24102022H7 (h)H 2022HH 2022H 2022HHH 20243 28A100,000,00020243 28613,720A10,333,513 H 20256 303,303,034A 20256 30 20256 30 3.21 20256 302025630 20256 30 (i) 20251 2320251 23 (ii) 20256 30 (iii) 20256 30 (iv) 20256 30 20256 30II. HH20212 2620213 1940,80020213 24H151.00H6,373.65,285.2 20224 2820238 30202412 20 20256 302,843.1 20256 30 20256 30 20256 30 20256 30 1. 20178 25A603127.SHH20212 266127.HK CRO 2. 3420258 26 202520243 34 2024 202412 31 3. •21 4. (a) 4(b)15 20256 302,300202412 312,200 4. (b) • (i)(ii)(iii) • (i)(ii)(iii) • (i) 4. (b) (i) 4. (b) (ii) (iii) 5. 6. (a) 6. (b) 401(k) 6. (c) 8. (a) 60,932,00020246 30169,742,000 (b) 60,932,00020246 30169,742,000 9. 85,551,00020246 30120,148,000 10. 10. (a) 10. (b) 202412 3120256 30 20256 303580,000 20256 3010%106,596,000202412 31106,890,000 12. 13. 20256 30248,905,00020246 30335,968,000 14. 15. (a) (b) 18. 19. 20256 30 20. 21. (a) 21. (b) 22. (a) 20256 3020246 30 (b) 20256 1820242024 •20240.03 202420258 23. 24. (a) 13 (b) 20256 30 24. (b) (i) 2025630918,000 20256 301,491,000 20256 304,238,000 24. (b) (i) 20256 30 25. 於2025年6月30日未於綜合財務報表撥備的未付資本承擔如下： 26. (a) 未經審核中期財務報告附註 26. JOINN Biologics Inc.(a) 26. (b) 26. (c) 2021Biorichland LLC 6,025,00043,140,00020256 30691,0004,965,000 2023 7,563,00020256 301,505,000 2023 2,429,00020256 30441,000 20242025 18,416,00020256 303,174,000 26. (d) (e) 20256 305,126,00020246 305,421,000